diosgenin has been researched along with angiotensin ii in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Yu, XF; Zhou, GM; Zhou, HT | 1 |
Chen, L; Lei, L; Li, Q; Li, T | 1 |
Jiang, W; Lei, L; Li, Q; Ni, Y; Wan, Z; Wei, J | 1 |
3 other study(ies) available for diosgenin and angiotensin ii
Article | Year |
---|---|
Diosgenin inhibits angiotensin II-induced extracellular matrix remodeling in cardiac fibroblasts through regulating the TGF‑β1/Smad3 signaling pathway.
Topics: Actins; Angiotensin II; Animals; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen Type I; Diosgenin; Extracellular Matrix; Fibroblasts; Fibronectins; Myocardium; Phosphorylation; Rats; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta1 | 2017 |
Dioscin ameliorates cardiac hypertrophy through inhibition of the MAPK and Akt/GSK3β/mTOR pathways.
Topics: Angiotensin II; Animals; Cardiomegaly; Diosgenin; Glycogen Synthase Kinase 3 beta; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Vasoconstrictor Agents | 2018 |
Polyphyllin I attenuates pressure over-load induced cardiac hypertrophy via inhibition of Wnt/β-catenin signaling pathway.
Topics: Angiotensin II; Animals; Cardiomegaly; Diosgenin; Disease Models, Animal; Echocardiography; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Rats; Wnt Signaling Pathway | 2020 |